Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 2/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912778 | 1.00 | USP28 (0.40) | USP28KMT2AMEN1SMN1; SMN2RIPK1 | |
| SCHEMBL26541078 | 0.79 | ALDH1A1 (0.38) | USP28KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2595400 | 0.78 | ACHE (0.48) | USP28KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12640806 | 0.77 | RIPK1 (0.40) | RIPK1ALDH1A1SLC6A4CES2CES1 | |
| SCHEMBL29912873 | 0.77 | RIPK1 (0.40) | RIPK1ALDH1A1SLC6A4CES2CES1 | |
| SCHEMBL17882408 | 0.76 | RIPK1 (0.41) | RIPK1CES2CES1 | |
| SCHEMBL4574550 | 0.75 | RIPK1 (0.42) | RIPK1CES2CES1 | |
| SCHEMBL4336057 | 0.75 | GSR (0.49) | USP28KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1967720 | 0.74 | RIPK1 (0.42) | RIPK1CES2CES1 | |
| SCHEMBL698821 | 0.73 | RIPK1 (0.44) | RIPK1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224237-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-115197098-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2023-08-08 | — | — | CN | disclosed |
| CN-115197098-A | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108467-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-08-19 | — | — | CN | disclosed |
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20180263934-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-20 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| CN-107108467-A | cell necrosis inhibitor | 北京生命科学研究所 | 2017-08-29 | — | — | CN | disclosed |
| WO-2008134035-A1 | ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134035-A1 | ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682319-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | USP28 963/4885KMT2A 4194/4885MEN1 3176/4885 |
| US-20170290790-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | USP28 1165/4885KMT2A 3654/4885MEN1 3275/4885 |
| US-20180263934-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | USP28 963/4885KMT2A 4194/4885MEN1 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.